Blog

TraceLink, Roche and SPI Win GS1 Brazil Automation Award for RDC 54 Compliance Pilot

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that the company has been awarded the 2015 GS1 Brazil Automation Award for its partnership with Roche and SPI in developing an ANVISA pilot solution to meet the Brazil RDC 54 track and trace regulation. TraceLink, Roche and SPI were recognized for their innovation and entrepreneurship in creating practical solutions based on industry standards to meet key business challenges at the GS1 Brazil award ceremony on November 11th in Sao Paulo Brazil.

 

Read More

Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis that Restores Activity of Mutant F508del CFTR Protein to 80% of Normal

Proteostasis Therapeutics, Inc. (PTI), a company developing small molecule therapeutics to treat diseases caused by defects in protein processing, announced today the expansion of its cystic fibrosis (CF) drug candidate pipeline to include the addition of a novel triple combination therapy of PTI’s own CFTR amplifiers, correctors and potentiators. PTI’s testing has shown that a triple combination comprising a proprietary corrector and potentiator, currently in late lead optimization stage, and one of PTI’s CFTR amplifiers, can restore the activity of mutant F508del CFTR protein to 80% of normal activity in Ussing chamber assays.

 

Read More

Aclaris Therapeutics Reports Third Quarter 2015 Financial Results

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015.

“We are very pleased with the completion of our initial public offering in early October, including the exercise in full of the underwriters’ option to purchase additional shares. The additional capital will provide Aclaris the ability to advance our proprietary pipeline, including our lead drug candidate A-101 for seborrheic keratosis, as we execute on our strategy to build a fully integrated dermatology company,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

 

Read More

PatientPing Announces $9.6M in Funding from Google Ventures, F-Prime Capital, and First Round to Build the First National Care Coordination Network

BOSTON, MA (November 16, 2015) — PatientPing, a company that connects healthcare providers across the country with real-time notifications when patients receive care, announced today that it has raised $9.6M led by Google Ventures and F-Prime Capital (the venture capital funds of FMR LLC, the parent company of Fidelity), with participation from First Round Capital and SV Angel.

Read the full press release here.

Driven by the changing incentives of the Affordable Care Act, providers are compelled to work with one another when they share patients. These new collaborations are bringing together historically disparate and siloed healthcare facilities in regional provider communities that more efficiently deliver high quality care wherever patients go. PatientPing is fueling this transition by providing a critical missing link for providers operating in this new environment: the ability to be notified instantly when a patient is receiving care anywhere – inside or outside of their facility or health system – and the ability to collaborate with providers to ensure the best health outcomes for patients.

Upon joining PatientPing, providers receive “Pings,” real-time notifications, whenever their patients receive care at any facility that is a part of the national PatientPing network. At the facility where patients are getting care, providers receive guidelines that include contact information for others on the patient’s care team, helpful instructions from the care team, and patient visit histories. By sharing this information in real-time, providers can seamlessly coordinate their patient’s care.

Semma Therapeutics Acquires Providence Biotech Company, CytoSolv, Inc.

A Cambridge, Mass., company, Semma Therapeutics, has acquired Providence-based CytoSolv, Inc., which has garnered local support since its founding in 2010 from the Slater Technology Fund and others, Slater announced Monday.

CytoSolv will continue to operate out of its recently expanded Providence location at 117 Chapman St.

No details about acquisition costs were disclosed, but Slater notes that Semma has recently announced $44 million of initial investment led by MPM Capital.

The co-founders of CytoSolv, Dr. Moses Goddard and Christopher Thanos, are now employees of the Cambridge company, according to a prepared statement from the Slater Technology Fund. Goddard is now chief medical officer, and Thanos is vice president of delivery. A principal CytoSolv scientist, Briannan Bintz, will be director of delivery at Semma.

Read More

TraceLink Ranked Number 293 Fastest Growing Company in North America on Deloitte’s 2015 Technology Fast 500(TM)

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that it has been ranked number 293 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. TraceLink, which achieved revenue growth of 236 percent from 2011 to 2014, is one of only 15 software companies from Massachusetts to be ranked on the 2015 Deloitte Technology Fast 500™, and is ranked number seven (7) among the fastest growing software companies headquartered in the state.

 

Read More

Tetraphase Pharmaceuticals to Provide Corporate Update at Stifel 2015 Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation, including an update on its eravacycline development program, at the Stifel 2015 Healthcare Conference on November 17, 2015 at 8:00 a.m. Eastern Time at The New York Palace Hotel in New York City.

Read More

Ultragenyx to Present at Upcoming Investor Conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced presentations at two upcoming investor conferences. Tom Kassberg, the company’s Chief Business Officer, will be presenting at the Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2015 at 8:40am GMT in London. Shalini Sharp, the company’s Chief Financial Officer, will be presenting at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 1:30pm ET in New York.

 

Read More

FORUM Pharmaceuticals Inc. Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program for Cognitive Impairment in Schizophrenia

FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of transformative medicines to treat serious brain diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed a partial clinical hold on the Phase 3 encenicline program for cognitive impairment in schizophrenia (CIS). This partial hold applied to a 26 week Phase 3 extension study. The two global Phase 3 efficacy and safety trials evaluating the use of encenicline to treat CIS are nearing completion, with top-line results anticipated in the first half of 2016.

 

Read More

WuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China

WuXi PharmaTech (Cayman) Inc. (NYSE:  WX) and Eli Lilly and Company (NYSE: LLY) today announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.

The potential medicine is a novel, once-daily oral agent, discovered by Lilly, which could address cardiovascular risk in patients with dyslipidemia, representing an unmet medical need worldwide. An estimated 276 million patients in China are affected by these conditions, including about 12 million patients requiring drug treatment. The potential medicine aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events.

WuXi will be responsible for regulatory, development and manufacturing activities in China, which will be led and coordinated by WuXi’s Product Development Service and Partnership (PDSP) Business Unit. The potential medicine will be manufactured in China by WuXi to support China development. Lilly will be responsible for commercial activities. The parties will both invest in bringing this potential new medicine to patients in China. Further financial terms of the collaboration were not disclosed. An Investigational New Drug (IND) application will be filed in China by WuXi, and product development and registration will be carried out within China.

 

Read More